Drugs / PRO 542
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000876 | ? → Nov 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00055185 | Apr 2003 → Jun 2005 | AIDS | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO 542 | “CD4-IgG2 (PRO 542)” NCT00055185 ↗ |
| Known as | CD4-IgG2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00055185 ↗ |
| Action | Inhibit | “built to block the entrance of HIV into CD4 cells” NCT00000876 ↗ |
| Modality | Protein / enzyme biologic | “CD4-IgG2 is a special man-made protein” NCT00000876 ↗ |
| Route | Intravenous | “patients receive a single dose of CD4-IgG2 intravenously” NCT00000876 ↗ |